RVT-1601

DRUG2 trials

Sponsors

Respivant Sciences GmbH

Conditions

Chronic CoughIPFPersistent Cough in IPFRespiratory Morbidities of Prematurity (RMP)

Phase 1

Open-label Study of Inhaled RVT-1601 in Preterm Infants

CompletedNCT04007120

Respivant Sciences GmbHRespiratory Morbidities of Prematurity (RMP)

Start: 2019-10-01End: 2020-05-29Updated: 2020-06-04

Phase 2

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

TerminatedNCT03864328

Respivant Sciences GmbHChronic Cough, IPF, Persistent Cough in IPF

Start: 2019-03-29End: 2020-06-05Updated: 2020-06-11